Oxo-chromen-iminomethyl-phenoxy-phenylacetamide-Cpd10f
Multimodal anti-Alzheimer agents targeting acetylcholinesterase (AChE), butyrylcholinesterase (BuChE) and glycogen synthase kinase-3beta (GSK-3beta). AChE IC50 3 +/- 0.1 nM; BuChE IC50 303 +/- 0.03 nM; GSK-3 inhibition 7.58 +/- 0.83 nM)
General
Type : Multitarget, Chromen, GSK-3 kinase inhibitor, Coumarin
Chemical_Nomenclature : 2-(4-((2-Oxo-2H-chromen-6-yl)imino)methyl)phenoxy-N-phenylacetamide
Canonical SMILES : C1=CC(=CC=C1OCC(NC2=CC=CC=C2)=O)C=NC3=CC=C4C(=C3)C=CC(O4)=O
InChI : InChI=1S\/C24H18N2O4\/c27-23(26-19-4-2-1-3-5-19)16-29-21-10-6-17(7-11-21)15-25-20-9-12-22-18(14-20)8-13-24(28)30-22\/h1-15H,16H2,(H,26,27)
InChIKey : DSFRFFASYBJUHO-UHFFFAOYSA-N
Other name(s) : Compound 10f
Target
Families : Oxo-chromen-iminomethyl-phenoxy-phenylacetamide-Cpd10f ligand of proteins in family
ACHE
BCHE
Protein :
human-ACHE
human-BCHE
References (1)
| Title : Development of coumarin-based acetylcholinesterase inhibitors: Synthesis, biological assessment and computational simulations - Emam_2026_Bioorg.Chem_173_109630 |
| Author(s) : Emam NE , Refaey RH , El-Ashrey MK , Mahmoud WR , Nissan YM , Seif EM |
| Ref : Bioorg Chem , 173 :109630 , 2026 |
| Abstract : |
| PubMedSearch : Emam_2026_Bioorg.Chem_173_109630 |
| PubMedID: 41691754 |